HUMAN PAPILLOMAVIRUS REACTIVATION

This adverse event was reported 13 times

These drugs are most commonly taken by patients reporting HUMAN PAPILLOMAVIRUS REACTIVATION:

# Drug Count
0 BORTEZOMIB 7
1 DARATUMUMAB 7
2 DEXAMETHASONE 7
3 DEXAMETHASONE 1.5 MG 7
4 PREDNISONE 2
5 RISANKIZUMAB-RZAA 2
6 UPADACITINIB 2
7 AZATHIOPRINE 1
8 IMIQUIMOD 1
9 SIBEPRENLIMAB 1
See all common drugs associated with HUMAN PAPILLOMAVIRUS REACTIVATION

HUMAN PAPILLOMAVIRUS REACTIVATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SIBEPRENLIMAB 1 0.0015
1 IMIQUIMOD 1 0.0004
2 BORTEZOMIB 7 0.0001
3 DEXAMETHASONE 1.5 MG 7 0.0000
4 UPADACITINIB 2 0.0000
5 DEXAMETHASONE 7 0.0000
6 VEDOLIZUMAB 1 0.0000
7 AZATHIOPRINE 1 0.0000
8 PREDNISONE 2 0.0000
See all drugs enriched for association with HUMAN PAPILLOMAVIRUS REACTIVATION

HUMAN PAPILLOMAVIRUS REACTIVATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD38-directed Cytolytic Antibody [EPC] 7 0.0012
1 Proteasome Inhibitor [EPC] 7 0.0001
2 Interleukin-23 Antagonist [EPC] 2 0.0000
3 Janus Kinase Inhibitor [EPC] 2 0.0000
4 Integrin Receptor Antagonist [EPC] 1 0.0000
5 Purine Antimetabolite [EPC] 1 0.0000
6 Corticosteroid [EPC] 9 0.0000
See all drug classes enriched for association with HUMAN PAPILLOMAVIRUS REACTIVATION